{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-021039","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2025-07-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.390378+00:00","generated_at":"2026-05-18T01:22:53.293267+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Calidi eliminates President role; approves 1-for-12 reverse stock split effective Aug 5, 2025","bullets":["Calidi eliminated the President, Medical & Scientific Affairs position held by Dr. Boris Minev, effective July 29, 2025; CMO Dr. Guy Travis Clifton assumes duties.","Reverse stock split at 1-for-12 ratio; shares expected to begin trading on split-adjusted basis on NYSE American at market open August 5, 2025.","Stockholders approved the reverse split on July 9, 2025; Board approved ratio on July 11, 2025; new CUSIP is 320703 408.","Fractional shares will be rounded up to the nearest whole share; no action required for book-entry or street name holders."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-021039","json":"https://secwatch.observer/filing/0001641172-25-021039.json","markdown":"https://secwatch.observer/filing/0001641172-25-021039.md","text":"https://secwatch.observer/filing/0001641172-25-021039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/0001641172-25-021039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000164117225021039/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T01:22:53.293267+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}